VIMTALABS
Vimta Labs Limited (VIMTALABS) Stock Analysis
Vimta Labs Limited provides analytical testing, clinical diagnostics, and contract research services from Hyderabad. It serves pharma, food, environmental, and government clients with accredited laboratories. The company is a established testing and CRO player in India. It is listed on Indian stock exchanges.
Healthcare › Diagnostics & Research
₹522.50
-2.79% 1W | -21.80% 52W
Market Cap
2.3k CR
P/E Ratio
29.6
52W High
₹735
52W Low
₹376.1
Div. Yield
0.38%
Beta
-0.1
50 DMA
₹612.4
200 DMA
₹525.8
Profit Margin
18.9%
Inst. Own.
4.5%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 67 | 74 | 79 | 80 | 77 | 82 | 83 | 66 | 75 | 80 | 75 | 85 | 90 |
| Expenses | 47 | 51 | 55 | 54 | 56 | 58 | 59 | 48 | 51 | 55 | 49 | 55 | 57 |
| Operating Profit | 21 | 23 | 24 | 25 | 21 | 24 | 25 | 17 | 24 | 24 | 26 | 30 | 33 |
| OPM % | 31% | 31% | 30% | 32% | 28% | 30% | 30% | 27% | 32% | 31% | 35% | 35% | 37% |
| Other Income | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | -1 | 0 | -1 | -1 | 5 |
| Interest | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 |
| Depreciation | 6 | 7 | 7 | 8 | 8 | 8 | 8 | 9 | 8 | 8 | 8 | 8 | 10 |
| Profit before tax | 15 | 16 | 17 | 18 | 14 | 17 | 16 | 8 | 14 | 16 | 17 | 20 | 28 |
| Tax % | 25% | 27% | 28% | 26% | 27% | 23% | 25% | 25% | 25% | 24% | 26% | 24% | 23% |
| Net Profit | 12 | 12 | 12 | 13 | 10 | 13 | 12 | 6 | 10 | 12 | 12 | 15 | 22 |
| EPS in Rs | 2.64 | 2.68 | 2.72 | 2.99 | 2.32 | 2.86 | 2.75 | 1.43 | 2.29 | 2.79 | 2.77 | 3.44 | 4.84 |
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|
| Sales | 181 | 211 | 278 | 318 | 318 | 329 |
| Expenses | 151 | 158 | 198 | 223 | 231 | 216 |
| Operating Profit | 30 | 53 | 80 | 95 | 87 | 113 |
| OPM % | 17% | 25% | 29% | 30% | 27% | 34% |
| Other Income | 3 | 1 | 0 | 3 | 4 | 4 |
| Interest | 4 | 2 | 2 | 3 | 2 | 2 |
| Depreciation | 21 | 23 | 23 | 31 | 34 | 34 |
| Profit before tax | 8 | 29 | 56 | 65 | 54 | 81 |
| Tax % | 17% | 25% | 26% | 26% | 25% | |
| Net Profit | 7 | 21 | 41 | 48 | 41 | 61 |
| EPS in Rs | 1.55 | 4.84 | 9.35 | 10.87 | 9.26 | 13.84 |
| Dividend Payout % | 0% | 21% | 11% | 9% | 11% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 15.0% | – | – |
| Profit CAGR | 24.0% | – | – |
Shareholding Pattern
Promoters36.67%
FIIs3.49%
DIIs1.42%
Public58.42%
Promoters35.99%
FIIs4.33%
DIIs0.87%
Public58.80%
Promoters35.89%
FIIs4.59%
DIIs0.11%
Public59.40%
Promoters35.85%
FIIs4.89%
DIIs0.13%
Public59.12%
Promoters35.66%
FIIs4.41%
DIIs0.37%
Public59.55%
Promoters37.25%
FIIs2.25%
DIIs2.14%
Public58.37%
Promoters36.92%
FIIs5.13%
DIIs1.50%
Public56.45%
Promoters36.70%
FIIs3.66%
DIIs1.43%
Public58.20%
Promoters35.85%
FIIs4.89%
DIIs0.13%
Public59.12%
Promoters35.66%
FIIs4.41%
DIIs0.37%
Public59.55%
VIMTALABS
Holdings Analysis
Key strengths & risk signals
57
Overall
61
Fundamental
54
Technical
Risks (4)
TOO MUCH PUBLIC HOLDING! 57.92% public ownership - higher volatility risk.
POOR YEAR! Stock declined 21.8% in the last year.
WEAK POSITION! Current price (522.5) is below both moving averages.
NEGATIVE MOMENTUM! Price declined across timeframes - down 2.8% (1 week), 12.7% (1 month), 6.6% (3 months).
Strengths (4)
FAIRLY VALUED! PEG of 1.72 indicates reasonable valuation.
BULLISH TREND! 50-day average (612.4) is above 200-day average (525.8) - positive signal.
OVERSOLD! RSI at 28.5 - potential bounce opportunity.
LOW VOLATILITY! Beta of -0.10 - stable stock, less market risk.
Fundamental & Technical Analysis
57Overall
61Fundamental
54Technical
Fundamental Breakdown
Growth Quality
21/30
Revenue CAGR: 8.9% (MODERATE, 8/15). Profit CAGR: 17.2% (VERY GOOD, 13/15).
Profit Margin
6/10
GOOD EFFICIENCY! 18.9% profit margin - above average profitability.
PEG Valuation
8/10
FAIRLY VALUED! PEG of 1.72 indicates reasonable valuation.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.38% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 57.92% public ownership - higher volatility risk.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (612.4) is above 200-day average (525.8) - positive signal.
Price Position
2/10
WEAK POSITION! Current price (522.5) is below both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
1/10
POOR YEAR! Stock declined 21.8% in the last year.
Volume Sentiment
15/30
BEARISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 140,045 vs down days: 153,210. Ratio: 0.91x
RSI
5/5
OVERSOLD! RSI at 28.5 - potential bounce opportunity.
52W Range
3/5
MID RANGE! Trading at 40.8% of 52W range - neutral zone.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 2.8% (1 week), 12.7% (1 month), 6.6% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of -0.10 - stable stock, less market risk.
VIMTALABS
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-07-24 | Concall PDF | |
| Q3FY262026-02-03 | Concall PDF | |
| Q2FY262025-11-10 | Concall PDF |
Peer Comparison
Healthcare · Diagnostics & Research · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIMTALABS | ₹522.50 | 29.6 | 18.9% | 8.9% | 17.2% | -21.8% | 57 | BREAKDOWN | +11.1% | -0.5% | +11.8% | -0.1% |
| KRSNAA | ₹533.30 | 18 | 11.6% | 16.6% | 17.8% | -32.4% | 61 | APPROACHING SUPPORT | -19.0% | -60.2% | +22.0% | +22.3% |
| SURAKSHA | ₹306.70 | 44.6 | 11.0% | 17.7% | 70.3% | +5.9% | 78 | BREAKDOWN | +38.3% | +106.3% | +20.7% | +7.6% |
| THYROCARE | ₹485.20 | 44 | 20.1% | 16.7% | 36.2% | +17.6% | 87 | BREAKDOWN | +34.2% | +10.8% | +24.4% | +7.1% |
| METROPOLIS | ₹530.40 | 54.6 | 11.8% | 12.8% | 10.0% | +7.9% | 67 | BREAKDOWN | +25.7% | +11.4% | +16.6% | +6.0% |
| VIJAYA | ₹1,381.70 | 76 | 21.9% | 21.0% | 26.9% | +41.3% | 74 | BREAKDOWN | +37.6% | +10.9% | +22.8% | +5.3% |
| SYNGENE | ₹386.10 | 70.3 | 6.1% | 5.4% | -12.0% | -40.0% | 57 | BOUNCE FROM SUPPORT | -110.4% | -106.1% | -15.8% | -29.0% |
| SAILIFE | ₹1,389.40 | 82.1 | 16.1% | 21.3% | 226.9% | +60.0% | 70 | BREAKDOWN | +21.2% | -29.7% | +11.7% | -7.9% |
Data from TradeAlone · Updated daily
